Phase 1 Study Supports Further Development of LRRK2 Inhibitor ARV-102
5 days ago · "The ability of ARV-102 to cross the blood-brain barrier and degrade the LRRK2 protein offers a potentially transformative therapeutic approach in the treatment of devastating neurodegenerative diseases," Noah Berkowitz, MD, PhD, chief medical officer at Arvinas, said in statement. 1 "We believe these results support continuing our ARV-102 ...
A Clinician’s Perspective on First-in-Human Data for LRRK2 Degrader ARV-102
1 day ago · This study provided the first-in-human data for ARV-102, supporting the continuation of the clinical program and building upon Arvinas' body of evidence for ARV-102 in its neuroscience pipeline. Following the completion of the Phase 1 trial in healthy volunteers, a Phase 1 trial of ARV-102 has been initiated in patients with Parkinson’s ...
Dosing of oral ARV-102 begins in healthy volunteers in Phase 1 trial
Feb 22, 2024 · A first participant has been dosed in Arvinas’ first-in-human Phase 1 trial testing ARV-102, its oral therapy candidate for neurodegenerative conditions, including Parkinson’s disease and progressive supranuclear palsy, or PSP, an atypical parkinsonian disorder.
Arvinas Announces First-in-Human Dosing of ARV-102, an
Feb 20, 2024 · In non-human primates, orally administered ARV-102 has been shown to reach deep-brain regions and degrade LRRK2 by nearly 90%. The Phase 1 clinical trial of ARV-102 is enrolling healthy volunteers at the Centre for Human Drug Research (CHDR) in …
Arvinas Presents First-in-Human Data for Investigational Oral …
Apr 4, 2025 · The ARV-102 Phase 1 study is designed to assess the safety, pharmacokinetics, and pharmacodynamics of orally administered ARV-102 in healthy male volunteers. This is a single-center, randomized, double-blind, placebo-controlled trial evaluating outcomes in both SAD and MAD cohorts.
Oral ARV-102 Crosses the Blood-Brain Barrier and Reduces CSF LRRK2 levels in NHPs. PK/PD of LRRK2 are reduced in cortex and CSF following oral dosing in NHP. Equivalent PK/PD supports the utility of measuring CSF LRRK2 as a surrogate for monitoring LRRK2 reductions in the brain. Plasma-free ARV-102 (M) LRRK2 (% Vehicle)
Investigational therapy ARV-102 now in Parkinson’s trial
Apr 9, 2025 · Arvinas has begun a Phase 1 clinical trial to test its investigational therapy ARV-102 in people with Parkinson’s disease, with Phase 1 data in healthy adults showing it was safe and worked as expected.
Arvinas Presents First-in-Human Data for Investigational Oral
Apr 4, 2025 · – Data demonstrate that ARV-102 was well tolerated, orally bioavailable, and brain-penetrant; ARV-102 achieved central and peripheral LRRK2 reduction indicating substantial LRRK2 protein ...
ARV-102 exposure measured by mass spectrometry. Circles indicate individual values. Box plot provides median and 25%/75% quartiles with whiskers to the last point within 1.5times the IQR.
Ozmosi | ARV-102 Drug Profile
Apr 4, 2025 · ARV-102 is a novel oral PROTAC® protein degrader designed to cross the blood-brain barrier and target leucine-rich repeat kinase 2 (LRRK2). In preclinical Increased activity and expressions of LRRK2 is genetically involved in the pathogenesis of neurological diseases including Parkinson’s disease and progressive supranuclear palsy.